Literature DB >> 15228501

Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats.

Udayasankar Arulmani1, Martin P Schuijt, Jan P C Heiligers, Edwin W Willems, Carlos M Villalón, Pramod R Saxena.   

Abstract

Several studies suggest that a calcitonin gene-related peptide (CGRP) receptor antagonist may have antimigraine properties, most probably via the inhibition of CGRP-induced cranial vasodilatation. We recently showed that the novel selective CGRP receptor antagonist, BIBN4096BS (1-piperidinecarboxamide, -N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-piperazinyl] carbonyl] pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl) methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, [[R-(R,(R*,S*)]), attenuated the CGRP-induced porcine carotid vasodilatation in a model predictive of antimigraine activity. In order to evaluate the potential safety of BIBN4096BS in migraine therapy, this study was designed to investigate the effects of intravenous BIBN4096BS on alpha-CGRP-induced systemic and regional haemodynamic changes in anaesthetised rats, using radioactive microspheres. In vehicle-pretreated animals, consecutive intravenous infusions of alpha-CGRP (0.25, 0.5 and 1 microg kg(-1) min.(-1)) dose-dependently decreased mean arterial blood pressure with an accompanying increase in heart rate and systemic vascular conductance whereas cardiac output remained unchanged. Alpha-CGRP also increased the vascular conductance to the heart, brain, gastrointestinal tract, adrenals, skeletal muscles and skin, whilst that to the kidneys, spleen, mesentery/pancreas and liver remained unaltered. The above systemic and regional haemodynamic responses to alpha-CGRP were clearly attenuated in BIBN4096BS (3 mg kg(-1) intravenously)-pretreated animals. These results indicate that exogenously administered alpha-CGRP dilates regional vascular beds via CGRP receptors on the basis of the antagonism produced by BIBN4096BS. Moreover, the fact that BIBN4096BS did not alter baseline haemodynamics suggests that endogenously produced CGRP does not play an important role in regulating the systemic and regional haemodynamics under resting conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228501     DOI: 10.1111/j.1742-7843.2004.pto940606.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  12 in total

1.  Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model.

Authors:  K Y Chan; S Gupta; R de Vries; A H J Danser; C M Villalón; E Muñoz-Islas; A Maassenvandenbrink
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

2.  [Pathophysiological role of calcitonin gene-related peptide (CGRP) in migraine and cluster headache].

Authors:  Karl Meßlinger
Journal:  Schmerz       Date:  2020-04       Impact factor: 1.107

3.  Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats.

Authors:  V H Avilés-Rosas; E Rivera-Mancilla; B A Marichal-Cancino; G Manrique-Maldonado; A H Altamirano-Espinoza; A Maassen Van Den Brink; C M Villalón
Journal:  Br J Pharmacol       Date:  2017-05-02       Impact factor: 8.739

4.  Neuropeptide release augments serum albumin loss and reduces ultrafiltration in peritoneal dialysis.

Authors:  Nicola Cavallini; Dick Delbro; Gunnar Tobin; Magnus Braide
Journal:  Perit Dial Int       Date:  2011-09-30       Impact factor: 1.756

5.  The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus.

Authors:  Michael Jochen Marco Fischer; Stanislav Koulchitsky; Karl Messlinger
Journal:  J Neurosci       Date:  2005-06-22       Impact factor: 6.167

6.  Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

Authors:  Simon R Sinclair; Stefanie A Kane; Bart J Van der Schueren; Alan Xiao; Kenneth J Willson; Janet Boyle; Inge de Lepeleire; Yang Xu; Lisa Hickey; William S Denney; Chi-Chung Li; John Palcza; Floris H M Vanmolkot; Marleen Depré; Anne Van Hecken; M Gail Murphy; Tony W Ho; Jay N de Hoon
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

Review 7.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

Review 8.  Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases.

Authors:  Abimael González-Hernández; Bruno A Marichal-Cancino; Jair Lozano-Cuenca; Jorge S López-Canales; Enriqueta Muñoz-Islas; Martha B Ramírez-Rosas; Carlos M Villalón
Journal:  Biomed Res Int       Date:  2016-12-27       Impact factor: 3.411

Review 9.  Monoaminergic Receptors as Modulators of the Perivascular Sympathetic and Sensory CGRPergic Outflows.

Authors:  Bruno A Marichal-Cancino; Abimael González-Hernández; Enriqueta Muñoz-Islas; Carlos M Villalón
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

10.  Percutaneous Trigeminal Nerve Stimulation Induces Cerebral Vasodilation in a Dose-Dependent Manner.

Authors:  Chunyan Li; Timothy G White; Kevin A Shah; Wayne Chaung; Keren Powell; Ping Wang; Henry H Woo; Raj K Narayan
Journal:  Neurosurgery       Date:  2021-05-13       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.